Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: russet who wrote (8482)	1/22/2002 3:40:13 PM
From: Cal Gary	Respond to of 14101

Good post Russet, Biovail may well be the best baseline to compare our DMX against. They're Canadian and a drug delivery technology company too, however using traditional oral and still suffer systematic side effect problems. But they counter that their drug time release makes the active drug safer. $11.418 Billion market cap! = 132mm shares out at $86.50 They also appear to win many (all?) legal wrangles. Must have lawyer insiders. <g> BVF also has taken a liking to PBP's Fibrostat wound healing technology. I don't think this is time release. They will be hiring 500 sales staff to handle US sales of recent drugs. Corporate Profile Biovail Corporation is a full-service pharmaceutical company that applies its proprietary drug delivery technologies in developing "oral controlled-release" products throughout North America. Biovail applies its proprietary drug delivery technologies to successful drug compounds that are free of patent protection to develop both branded and generic oral controlled-release products. The branded oral controlled-release products improve on existing formulations, providing better therapeutic and economic benefits. Biovail engages in the formulation, clinical testing, registration, manufacturing and marketing of these oral controlled-release products throughout North America. To date, Biovail technologies have been used to develop 18 products which have generated in excess of $400 million in worldwide sales per annum. These proven technologies are being applied to 16 new Biovail products currently under development. Click on the links below for further information about Biovail.